Companies /Healthcare

Cencora Inc

NYSE: COR Medical Distribution
$350.56
▼ $6.38 (−1.79%) today
Markets closed · 8:45am ET

24/7 Wall St. View

COR at a Glance

Valuation
Market cap
$66.9B
P/E ratio
19.9
Dividend yield
0.67%
Profitability
Revenue (TTM)
$337.4B
Profit margin
1.0%
EPS (TTM)
$17.63
Price
52-week range
$243 – $375
24/7 target
$421.66
Street target
$382.42
Earnings
Next report
Feb 2, 2027
Q4 2026 EPS
$4.66
vs. $4.57 est.
+1.9%

Headquartered in Conshohocken, PA Fiscal year ends September NYSE: COR cencora.com

About Cencora

Cencora, Inc. (NYSE: COR) is a global pharmaceutical solutions company that distributes pharmaceuticals and healthcare products and provides related services. It serves pharmaceutical manufacturers, health systems, retail pharmacies, physician practices, alternate sites of care and animal health customers.

In fiscal 2026 it reported through two reportable segments plus Other:
- **U.S. Healthcare Solutions:** U.S. wholesale and specialty distribution, including GLP-1 and specialty products, and physician practice/MSO platforms such as OneOncology (acquired February 2026) and Retina Consultants of America (acquired January 2025).
- **International Healthcare Solutions:** International distribution, Canadian operations including Innomar, and global specialty logistics through World Courier.
- **Other:** Businesses under strategic review, including MWI Animal Health (pending merger with Covetrus), Profarma (stake being sold) and parts of PharmaLex.

Beginning in fiscal 2027, Cencora will report two new segments plus Other:
- **Pharmaceutical Distribution and Services:** U.S. and international wholesale pharmaceutical distribution and related services.
- **Specialty Pharmaceutical and Provider Services:** Specialty distribution to physician practices, management services organizations, World Courier and 3PL services, Innomar and strategic parts of PharmaLex.

The company has also agreed to acquire American Oncology Network. Annual revenue exceeds $300 billion. Updated

Revenue by Segment · Q4 2026
  1. U.S. Healthcare Solutions89%
  2. International Healthcare Solutions9%
  3. Other3%

Latest Activity

TAKTakeda Pharmaceutical
52-week high
$21.44
+0.89%vs prior 52-week high · Nov 5, 2026

Takeda's $21.44 close tops the high it set on Nov. 5 by 0.89%, extending a steady climb in the large-cap drugmaker.

Related stockstoday
  • CORCencoraCustomer+2.8%
    Jun 17, 6:06 AM ET · SEC 10-K
  • CAHCardinal HealthCustomer+1.1%
    Mar 31, 2026 · SEC 10-K
  • JNJJohnson & JohnsonPartner+0.9%
    Jun 17, 6:06 AM ET · SEC 10-K

Moves: Nov 13, 2026 · Alpha Vantage daily close

8 more related stocks · 1 has no US listing

CORCencora
After-hours
$339.52
-5.25%open $358.32

A 5.25% slide to $339.53 from a $358.32 open is a sharp single-session move for a $64.8 billion distributor, and it came after Cardinal Health, a competitor, reported a Q1 FY2027 beat. Cencora has moved following 4 of 4 recent Cardinal reports.

CORCencora
Regular session
$343.79
-4.06%open $358.32

A 4.06% slide to $343.79 from a $358.32 open lands the same session Cardinal Health, a competitor, posted a Q1 FY2027 beat, a pattern that has followed 4 of 4 Cardinal reports with a 4.0% average move.

MCKMcKesson
Regular session
$1065.70
+4.57%open $1019.10

A 4.57% jump to $1,065.70 adds roughly $5 billion to this $124 billion distributor, and it comes after Cencora, a competitor, filed Q4 earnings. McKesson has followed 3 of the last 4 Cencora reports with an average 4.4% move.

Fiscal 2026 was a pivotal year for Cencora, as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of our portfolio and delivered record results.

Mauch is framing the $65 billion distributor as an oncology services owner, with OneOncology anchoring the MSO platform on the fiscal 2026 earnings call. The payoff investors should track is whether those practice economics keep lifting margins in fiscal 2027.

As we enter fiscal 2027, our new operating model is designed to strengthen our execution and provide visibility to our progress.

Cencora's CEO is reorganizing how the $65 billion distributor reports its business heading into fiscal 2027, which means new segment disclosure and a fresh baseline for judging management against guidance. Anyone modeling the drug wholesaler off prior-year segments needs to rebuild.

CORCencora
Q4 2026
EPS
$4.66
est $4.57+1.9%
Revenue
$88.35B
est $87.91B+0.5%

Cencora guided fiscal 2027 adjusted EPS to $19.40 to $19.75, implying 8% to 10% growth, after a fifth straight quarterly beat. OneOncology did the heavy lifting, and the dividend was raised to $0.66 a share.

Quarterly EPS — reported vs estimate
Now director at Cencora, Inc.

The $59 billion drug distributor just put a career logistics operator in the boardroom: Sanchez ran Ryder System as CEO before this seat went effective October 1. Supply chain execution is the whole game in pharmaceutical distribution, and the board now reflects that.

COR Coverage

1:19pm ET
Investing

Will MicroStrategy Be Next To Issue a Stock Split?

24/7 Wall Street Insights MicroStrategy’s Business Intelligence software is used by many large corporations, such as WalMart. MicroStrategy has intentionally let the software business slow down to focus on Bitcoin (BTC) acquisition,…

John Seetoo

Frequently Asked Questions

What does Cencora do?

Cencora, Inc. (NYSE: COR) is a global pharmaceutical solutions company that distributes pharmaceuticals and healthcare products and provides related services. It serves pharmaceutical manufacturers, health systems, retail pharmacies, physician practices, alternate sites of care and animal health customers.

What is the COR stock price target?

24/7 Wall St.'s 12-month price target for COR is $421.66, rated Buy. The Wall Street consensus target is $382.42. COR price prediction →